OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kelly on Trials Evaluating Frontline Immunotherapy Combinations in ESCC

February 23rd 2023

Ronan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.

Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate Cancer

February 23rd 2023

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

Dr. Grivas on the Real-World Study of Avelumab Maintenance in Metastatic Urothelial Carcinoma

February 23rd 2023

Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer.

Dr. Harding on the Evolution of Frontline Chemotherapy Approaches in Advanced Biliary Tract Cancer

February 23rd 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

Dr. Kaklamani on Racial Disparities and Clinical Outcomes in the RxPONDER Trial in Breast Cancer

February 22nd 2023

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

Dr. Contreras on the Use of Surgical Resection in Desmoplastic Melanoma

February 22nd 2023

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

Dr. Daneshmand on Erdafitinib in NMIBC

February 22nd 2023

Siamak Daneshmand, MD, discusses findings from the interim analysis of cohort 3 of the multicohort phase 2 THOR-2 trial.

Dr. Efstathiou on Niraparib Plus Abiraterone Acetate in mCRPC

February 22nd 2023

Eleni Efstathiou, MD, PhD, discusses second interim findings from a subgroup analysis of the phase 3 MAGNITUDE trial in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr. Atkins on TFS Outcomes from the HCRN GU16-260 Trial in RCC

February 22nd 2023

Michael B. Atkins, MD, discusses the treatment-free survival outcomes from cohort A of the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr. Sridhar on the Long-Term Data from the JAVELIN Bladder 100 Trial in Advanced Urothelial Carcinoma

February 22nd 2023

Srikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.

Dr. Harding on the Prevalence of TSC1/2 Mutations in GI Cancer

February 22nd 2023

James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.

Dr. Blackwood on the Implementation of the I SPY2 Trial in Breast Cancer

February 22nd 2023

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

Dr. Zhang on the Use of PARP Inhibitor–based Combinations in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Dr. Ramnaraign on the Investigation of Atezolizumab Plus Tivozanib in CRPC

February 20th 2023

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Dr. Roy on the Effect of Neoadjuvant Chemotherapy on OS in Sarcomatoid Bladder Cancer

February 20th 2023

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid muscle-invasive bladder cancer.

Dr. McGregor on Cabozantinib Plus Atezolizumab in Non–Clear Cell RCC

February 20th 2023

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

Dr. Bamias on Final Analysis of Atezolizumab Monotherapy in the IMvigor130 Trial in mUC

February 18th 2023

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Dr. Albigès on the CaboPoint Trial in Advanced RCC

February 18th 2023

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.

Dr. Gulhati on Current Treatment Approaches in Pancreatic Cancer

February 18th 2023

Prateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.

Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma

February 18th 2023

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.